H Lundbeck A/S (CO:HLUN-B) — Market Cap & Net Worth
Market Cap & Net Worth: H Lundbeck A/S (HLUN-B)
H Lundbeck A/S (CO:HLUN-B) has a market capitalization of $5.37 Billion (Dkr34.29 Billion) as of June 17, 2026. Listed on the CO stock exchange, this Denmark-based company holds position #3449 globally and #22 in its home market, demonstrating a -3.48% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying H Lundbeck A/S's stock price Dkr43.24 by its total outstanding shares 793128424 (793.13 Million). Review HLUN-B liabilities breakdown to assess the company's total debt and financial obligations.
H Lundbeck A/S Market Cap History: 2015 to 2026
H Lundbeck A/S's market capitalization history from 2015 to 2026. Data shows growth from $5.55 Billion to $5.37 Billion (1.21% CAGR).
H Lundbeck A/S Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how H Lundbeck A/S's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.22x
H Lundbeck A/S's market cap is 0.22 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.68x
H Lundbeck A/S's market cap is 1.68 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $6.78 Billion | $15.63 Billion | $1.21 Billion | 0.43x | 5.60x |
| 2017 | $7.43 Billion | $17.23 Billion | $2.62 Billion | 0.43x | 2.83x |
| 2018 | $6.73 Billion | $17.88 Billion | $3.91 Billion | 0.38x | 1.72x |
| 2019 | $6.00 Billion | $17.36 Billion | $2.67 Billion | 0.35x | 2.25x |
| 2020 | $4.93 Billion | $17.67 Billion | $1.58 Billion | 0.28x | 3.12x |
| 2021 | $3.98 Billion | $16.30 Billion | $1.32 Billion | 0.24x | 3.02x |
| 2022 | $3.11 Billion | $18.25 Billion | $1.92 Billion | 0.17x | 1.62x |
| 2023 | $3.98 Billion | $19.91 Billion | $2.29 Billion | 0.20x | 1.74x |
| 2024 | $5.13 Billion | $22.00 Billion | $3.14 Billion | 0.23x | 1.63x |
| 2025 | $5.36 Billion | $24.35 Billion | $3.19 Billion | 0.22x | 1.68x |
Competitor Companies of HLUN-B by Market Capitalization
Companies near H Lundbeck A/S in the global market cap rankings as of June 17, 2026.
Key companies related to H Lundbeck A/S by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #512 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #560 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #613 globally with a market cap of $44.69 Billion USD ( CN¥305.43 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #629 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #512 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #560 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.41 |
| #613 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.69 Billion | CN¥47.88 |
| #629 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
H Lundbeck A/S Historical Marketcap From 2015 to 2026
Between 2015 and today, H Lundbeck A/S's market cap moved from $5.55 Billion to $ 5.37 Billion, with a yearly change of 1.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Dkr5.37 Billion | +0.19% |
| 2025 | Dkr5.36 Billion | +4.45% |
| 2024 | Dkr5.13 Billion | +28.84% |
| 2023 | Dkr3.98 Billion | +28.12% |
| 2022 | Dkr3.11 Billion | -22.04% |
| 2021 | Dkr3.98 Billion | -19.13% |
| 2020 | Dkr4.93 Billion | -17.92% |
| 2019 | Dkr6.00 Billion | -10.86% |
| 2018 | Dkr6.73 Billion | -9.40% |
| 2017 | Dkr7.43 Billion | +9.64% |
| 2016 | Dkr6.78 Billion | +22.05% |
| 2015 | Dkr5.55 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of H Lundbeck A/S was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.37 Billion USD |
| MoneyControl | $5.37 Billion USD |
| MarketWatch | $5.37 Billion USD |
| marketcap.company | $5.37 Billion USD |
| Reuters | $5.37 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About H Lundbeck A/S
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat maj… Read more